Federal Court Orders FDA to Reconsider Mifepristone Restrictions After Arbitrary Ruling

A U.S. district court's order forces a regulatory review that could reshape medication abortion access at a moment when federal and state restrictions are compounding.

U.S. District Judge Robert S. Ballou, sitting in the Western District of Virginia, issued a ruling Friday ordering the Food and Drug Administration to reconsider existing restrictions on mifepristone, finding those restrictions to be arbitrary and capricious under the Administrative Procedure Act, according to court documents reviewed by The Guardian (July 2026). The ruling does not overturn the restrictions outright but compels the FDA to conduct a formal review and provide reasoned justification for maintaining them.

Judge Ballou's order noted that prior FDA reviews have, in his words, 'steadfastly found' mifepristone to be safe, according to the court filing cited by The Guardian. The APA standard of 'arbitrary and capricious' is the same legal threshold applied in major regulatory challenges, including the 2024 Supreme Court case Alliance for Hippocratic Medicine v. FDA, in which the Court ultimately ruled that the plaintiffs lacked standing without addressing mifepristone's safety on the merits (Supreme Court opinion, June 2024).

The FDA currently requires mifepristone to be dispensed under its Risk Evaluation and Mitigation Strategy (REMS) program, which mandates certification for prescribers and pharmacies. The agency imposed additional restrictions in 2023 that expanded mail-order access while retaining the REMS framework. The specific restrictions Judge Ballou found unsupported by the agency's own safety record were not enumerated in available public reporting at time of publication; the full court order, filed in the Western District of Virginia, would specify each contested restriction.

The Trump administration has not issued a public statement responding to the ruling as of July 24, 2026. The administration's broader posture on reproductive health regulation has involved reducing federal enforcement actions related to abortion access, though no executive order directly addressing mifepristone's REMS classification has been identified in public records available to this publication.

What remains unknown is the timeline the court has set for the FDA's reconsideration, the precise scope of restrictions under review, and whether the Department of Justice will appeal the order. The full docket of the Western District of Virginia case would answer each of those questions, and the FDA's forthcoming response filing will determine the next procedural step.